
Agentic AI Is Moving Into Healthcare as Clinical Agents Get More Autonomous
Agentic AI is moving into healthcare as ARPA-H, researchers and health systems test clinical agents that can use tools, manage workflows and escalate care.
Explore the latest biotech and health technology news, from medical devices and healthcare AI to genetics, synthetic biology and scientific research. TechAmerica.ai covers medical robotics, digital health, clinical trials, biotech startups, drug development, breakthrough therapies and investment trends shaping healthcare innovation around the world.
63 articles · page 4 of 6 · showing 37 to 48

Agentic AI is moving into healthcare as ARPA-H, researchers and health systems test clinical agents that can use tools, manage workflows and escalate care.

AI medical scribes, ambient AI healthcare, Microsoft Dragon Copilot, Abridge, Nabla, clinical documentation AI, healthcare AI

AI is moving into handheld ultrasound, digital stethoscopes and portable ECG devices, bringing automated analysis closer to patients and clinicians.

Explore 10 medical device companies integrating AI into ultrasound, imaging, endoscopy, surgical robotics, and other clinical equipment.

Philips has introduced Alturion, a new ultrasound system that uses AI-assisted measurements and workflow automation to support busy hospital imaging teams.

Healthcare benefits platform Thatch raised $108 million at a $1 billion valuation as employers seek lower-cost health insurance options.

Smart ring maker Oura files for an IPO after reporting strong revenue growth, millions of rings sold, and expanding AI health data.

Outer Biosciences uses living human skin and machine learning to discover new cosmetic ingredients, keeping tissue viable for up to four weeks in the lab.

Science Corporation has secured European regulatory approval for its PRIMA vision-restoring implant, bringing the brain-computer interface technology closer to commercial use for patients…

Colossal Biosciences is reportedly seeking fresh funding at a valuation of $20 billion to $30 billion as the de-extinction startup expands its biotechnology, AI and conservation businesses.

OpenAI researcher Miles Wang is reportedly leaving the company to launch an AI drug discovery startup, with funding talks valuing the venture at about $2 billion.

Musely has secured $360 million in non-dilutive funding from General Catalyst, allowing the company to expand without giving up equity.